Cellectar Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort in Phase 2 Trial of CLR 131 Dec 6, 2017
Cellectar Announces Updated Median Overall Survival of 26.2 Months from Cohort 1 of CLR 131 Phase 1 Trial in Advanced Multiple Myeloma Nov 7, 2017
Cellectar Biosciences to Host Conference Call on November 10, 2017 to Report Third Quarter 2017 Financial Results and Corporate Performance Nov 2, 2017
New Preclinical Data Suggest That Cellectar Biosciences’ PDC Platform Provides Enhanced Outcomes in Combination with External Radiation Oct 30, 2017
Cellectar Biosciences Introduces Multiple Dose Regimen in Fifth Cohort of Phase 1 Trial of CLR 131 in Multiple Myeloma Oct 24, 2017
Cellectar Biosciences Receives Additional Japanese Patent for CLR 131 and CLR 125 for the Treatment of Various Solid Tumors Oct 17, 2017
Cellectar Biosciences Announces Successful Completion of $7.76 Million Registered Direct Offering Oct 12, 2017
Cellectar Biosciences Announces $7.76 Million Registered Direct Offering Priced At-The-Market Oct 10, 2017